Spectrum of cardiac abnormalities associated with long QT in stroke survivors

Heart

Volumn 91, Issue 10, 2005, Pages 1306-1310

  Wong, Kenneth Y K ^a,b   McSwiggan, S ^b   Kennedy, N S J ^c   Wong, S Y S ^c   Gavin, A ^b   MacWalter, R S ^b   Struthers, A D ^b  

^a NATIONAL HEALTH SERVICE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE PERFUSION; HEART RATE VARIABILITY; HUMAN; LONG QT SYNDROME; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STROKE; SURVIVAL; CARDIOMYOPATHY; ELECTROCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; MIDDLE AGED; SINGLE BLIND PROCEDURE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CARDIOMYOPATHIES; CEREBROVASCULAR ACCIDENT; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; LONG QT SYNDROME; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; VENTRICULAR DYSFUNCTION, LEFT;

EID: 25144477036     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.045187     Document Type: Article

References (20)

1. Wong KYK, MacWalter RS, Douglas D, et al. Long QTc predicts future cardiac death in stroke survivors. Heart 2003;89:377-81.
2. Barr CS, Naas A, Freeman M, et al. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994;343:327-9.
3. Sohn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83.
4. European Society of Cardiology. North American Society of Pacing and Electrophysiology. Task force or the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation 1996;93:1043-65.
5. Huikuri HV, Mäkikallio T, Airaksinen KE, et al. Measurement of heart rate variability: a clinical tool or a research toy? J Am Coll Cardiol 1999;34:1878-83.
6. Perlini S, Muiesan ML, Cuspidi C, et al. Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry. Circulation 2001;103:678-83.
7. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998;97:48-54.
8. Kannel WB. Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J 1992;13(suppl D):82-8.
9. Dahlöf B, Devereux RB, Kjeldsen SE, for the LIFE study group, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
10. Mathew J, Sleight P, Lonn E, et al. Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001;104:1615-21.
11. Struthers AD, Davies J. Should we add screening for and treating left ventricular hypertrophy to the management of all patients needing secondary prevention of cardiovascular disease? Q J Med 2003;96:449-52.
12. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358: 1033-41,
13. Erratum in: Lancet 2001;358:1556,
14. Lancet 2002;359:2120.
15. Witham MD, Davies JI, Dawson A, et al. Hypothetical economic analysis of screening for left ventricular hypertrophy in high-risk normotensive populations. Q J M 2004;97:87-93.
16. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-HEART). Circulation 1998;98:1510-6.
17. Korkmaz ME, Müderrisoǧlu H, Uluçam M, et al. Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischaemic heart failure. Am J Cardiol 2000;86:649-53.
18. Mortara A, La Rovere MT, Pinna GD, et al. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroreflex gain and heart rate variability in patients with stable chronic heart failure. J Am Coll Cardiol 2000;36:1612-8.
19. Lin JL, Chan HL, Du CC, et al. Long-term β-blocker therapy improves autonomic nervous regulation in advanced congestive heart failure: a longitudinal heart rate variability study. Am Heart J 1999;137:658-65.
20. Rodriguez CJ, Sacco RL, Sciacca RR, et al. Physical activity attenuates the effect of increased left ventricular mass on the risk of ischemic stroke: the Northern Manhattan stroke study. J Am Coll Cardiol 2002;39:1482-8.